Semax

Also referred to as Semax peptide, ACTH(4-10) analogue.

Status: Investigational. Semax is not an FDA-approved drug product in the United States and has no FDA-recognized indication here. It is registered as a medicine in Russia for specific neurological uses under Russian regulatory authority, but a foreign registration is a decision by a different country's regulator, made against a different evidentiary standard, and it does not transfer to the United States in any form. In the US, Semax exists only as a research chemical and, where offered at all, an unapproved compounded preparation whose legal status a patient and physician must verify independently.

Semax is a synthetic peptide derived from a fragment of adrenocorticotropic hormone (ACTH) that has been studied in Russia for decades and is registered there as a medicine for certain neurological indications. It is not an FDA-approved drug product in the United States, and its Russian registration does not establish safety or effectiveness under US regulatory standards. Patient interest generally centers on attention, mental fatigue, and stress recovery. The English-language human evidence base is thin compared to the Russian literature, and independent replication under modern trial standards is limited.

What it is

Semax is a synthetic heptapeptide built from a short sequence found in ACTH, modified to resist rapid breakdown by peptidases. It does not act as a hormone in the way ACTH itself does; researchers describe it instead as a neuropeptide-like compound intended to act on the central nervous system. It has been manufactured in Russia as a nasal formulation for use under that country's drug regulatory framework.

Why people ask about it

Patients typically ask about Semax after encountering claims about focus, memory, or resilience to stress in online nootropic communities. Some are aware of its formal registration abroad and understandably wonder whether that status means it is safe or effective by US standards. Others are exploring alternatives to stimulant medications and want to understand what, if anything, has been rigorously shown.

Proposed mechanism

The proposed mechanisms come largely from Russian laboratory and animal studies and are not established in well-controlled human trials. Researchers have proposed effects on brain-derived neurotrophic factor (BDNF) signalling, on monoamine neurotransmitter turnover, and on markers of neuronal stress response. These are hypotheses generated mostly in rodent models and in vitro systems, and it is proposed rather than demonstrated that they explain any effect in people. The ACTH-derived backbone has led to proposed, unconfirmed effects on central stress-axis signalling distinct from ACTH's peripheral hormonal role.

What researchers have studied

• Effects on BDNF expression and neurotrophic signalling in animal models
• Behavioral measures of attention and learning in rodent studies
• Small Russian clinical studies in stroke recovery and specific neurological conditions
• Nasal absorption and central nervous system delivery of peptide fragments
• Comparisons with ACTH fragments studied historically for cognitive effects

Human evidence

• Most published human studies originate from Russian research groups and were conducted under regulatory and methodological standards that differ from FDA/ICH trial norms.
• Sample sizes in the available literature are generally small, and many studies lack the blinding, placebo control, or independent replication expected in modern trial design.
• Independent, peer-reviewed replication outside Russia is limited, so the applicability of these findings to a general US population is not established.
• No large randomized controlled trials meeting current international standards for cognition or mood outcomes in healthy adults were identified.

Preclinical evidence

• Animal studies report changes in BDNF and related neurotrophic markers after Semax administration.
• Rodent behavioral studies report altered performance on learning and memory tasks under specific experimental conditions.
• Cell-based studies describe effects on neuronal stress-response pathways.
• Animal models of ischemia report changes in outcome measures, forming part of the rationale for its use in stroke recovery in Russia.

What is not yet known

• Whether effects observed in Russian trials replicate under blinded, placebo-controlled conditions with modern methodology.
• Long-term safety with repeated use over months or years.
• Optimal population, timing, or clinical context for any proposed benefit.
• How findings in stroke or neurological injury models, if valid, relate to use by healthy adults seeking cognitive benefit.
• Interaction risk with other centrally acting medications.
• Consistency and purity of research-grade or compounded material available outside Russia's regulated supply chain.

Regulatory status and access

Some compounding pharmacies have prepared Semax on a physician's order, but compounding is not FDA approval and does not certify the safety, purity, or effectiveness of the resulting product for any use. Whether a given preparation is currently permissible depends on evolving FDA and state pharmacy board positions that must be checked at the time of any conversation, not assumed from this page. Ask about current availability. Only a physician can determine whether discussing Semax further is appropriate after an individual evaluation.

Known and potential risks

• Absence of FDA review means US supply chains for Semax are unregulated, and product identity, purity, and sterility cannot be assumed.
• Long-term human safety data outside the Russian clinical experience is sparse.
• Unknown interactions with stimulants, antidepressants, or other centrally acting drugs.
• Mislabeled or contaminated research-chemical product is a documented risk across the unregulated peptide market generally.
• Self-directed use without physician oversight removes the ability to monitor for unexpected effects.

Cautions and who may not be a candidate

• Pregnancy and breastfeeding, where no safety data exist.
• Undiagnosed neurological or psychiatric symptoms that need direct medical evaluation rather than self-treatment.
• Known adrenal or pituitary axis disorders, given the ACTH-derived structure.
• Concurrent use of other centrally acting investigational compounds without physician coordination.
• History of seizure disorder, where central nervous system-active peptides warrant specific caution.

Questions to discuss with a physician

• What is the current US legal and regulatory status of Semax, and has that changed recently?
• How does Russian registration differ from FDA approval in terms of evidence required?
• What would we actually be able to monitor if this were discussed further?
• Are there FDA-approved alternatives that address my underlying concern more directly?
• What is known about product quality if a compounded version is considered?
• How would we know if it was not working, or was causing harm?

Frequently asked questions

Is Semax FDA-approved?

No. Semax is not an FDA-approved drug product in the United States. It is registered as a medicine in Russia for specific uses, but that is a decision by a different country's regulator and does not extend to or substitute for FDA approval.

Does GOAL.MD sell Semax?

This page is educational and does not constitute an offer to sell or ship Semax. Ask about current availability, and a physician determines appropriateness only after an individual evaluation.

Why is Semax registered in Russia but not here?

Different countries set their own evidentiary bar for drug registration. Russia's registration reflects its own regulatory process and clinical experience; the United States requires separate, independent evidence submitted to and reviewed by the FDA, which has not occurred for Semax.

What has actually been studied with Semax?

Research includes animal studies of neurotrophic signalling and behavior, along with smaller Russian clinical studies in specific neurological contexts such as stroke recovery. Independent replication under modern trial standards outside Russia is limited.

Is Semax the same as ACTH?

No. Semax is derived from a fragment of ACTH's structure but is engineered to resist breakdown and is studied for proposed central nervous system effects distinct from ACTH's role as an adrenal-stimulating hormone.

Can Semax improve memory or focus?

Some studies report changes in attention-related and learning measures, mostly in small trials or animal models. This is not the same as an established, general benefit, and no such claim can be made for a broad population.

Is Semax safe?

Long-term human safety data outside the Russian clinical experience is limited, and product sourced outside a regulated supply chain carries additional identity and purity risk. This is a question to raise directly with a physician rather than assume.

How is Semax different from Selank?

Both are Russian-developed peptides studied for central nervous system effects, but they differ in structure and research emphasis; Semax research leans toward attention and neurological recovery, while Selank research leans toward anxiety-related outcomes.

Who should not consider discussing Semax?

Anyone who is pregnant or breastfeeding, has an undiagnosed neurological or psychiatric symptom, or has an adrenal or pituitary condition should raise those specifics with a physician before any such discussion proceeds.

What would a physician need to know before discussing Semax?

A complete medical history, current medications, and the specific concern prompting interest, so that appropriateness and any monitoring plan can be assessed individually.

This page is educational. Nothing here can be ordered, and nothing here is a prescription or medical advice. Compounded preparations are not FDA-approved. To ask about current availability, visit goal.md/peptides/connect or call or text 314-907-3103.

Medically reviewed by Michael Fitch, MD, MD. Last reviewed 2026-08-13.